Brokerages expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to report earnings per share of ($0.23) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.21). AcelRx Pharmaceuticals reported earnings per share of ($0.21) during the same quarter last year, which indicates a negative year-over-year growth rate of 9.5%. The company is expected to issue its next earnings results on Friday, November 1st.
According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.72). For the next financial year, analysts forecast that the business will post earnings of ($0.71) per share, with EPS estimates ranging from ($0.89) to ($0.53). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Monday, August 5th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The business had revenue of $0.94 million for the quarter, compared to analysts’ expectations of $1.55 million.
A number of analysts have issued reports on ACRX shares. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Thursday, May 9th. Credit Suisse Group began coverage on AcelRx Pharmaceuticals in a research report on Monday, August 5th. They set an “outperform” rating and a $7.00 price objective for the company. ValuEngine downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Finally, BidaskClub downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.47.
NASDAQ:ACRX traded down $0.05 on Friday, reaching $2.20. 811,052 shares of the company’s stock were exchanged, compared to its average volume of 1,028,517. The company has a quick ratio of 11.34, a current ratio of 11.69 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $178.73 million, a price-to-earnings ratio of -2.72 and a beta of 2.14. The business has a fifty day moving average of $2.49 and a 200-day moving average of $2.89. AcelRx Pharmaceuticals has a 52-week low of $1.99 and a 52-week high of $5.05.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Resources Investment Advisors Inc. acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $34,000. Parametric Portfolio Associates LLC acquired a new position in AcelRx Pharmaceuticals in the second quarter valued at approximately $26,000. WINTON GROUP Ltd acquired a new position in AcelRx Pharmaceuticals in the second quarter valued at approximately $40,000. Ahrens Investment Partners LLC acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $108,000. Finally, Weiss Asset Management LP acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $113,000. 19.13% of the stock is owned by hedge funds and other institutional investors.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Read More: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.